Clinical Advancements in HIV Education Center

According to the CDC, a significant proportion of patients who know they are infected with HIV and are prescribed antiretroviral therapy (ART) do not attain adequate virologic and immunologic responses due to treatment burdens, including poor retention in care, nonadherence, unfavorable pharmacokinetics, or other biologic or socioeconomic factors. However, research and treatment advances aimed at reducing pill-burden, treatment resistance, proactive prevention, early detection, and rapid treatment initiation are changing how HIV is treated.

This Education Center is intended to update clinicians on the latest developments in HIV research and treatment in order to help them manage patients with the disease.

FDA Grants Breakthrough Therapy Designation For Long-Acting Cabotegravir As HIV PrEP

FDA Grants Breakthrough Therapy Designation For Long-Acting Cabotegravir As HIV PrEP

FDA has granted the long-acting injectable cabotegravir Breakthrough Designation Therapy for HIV pre-exposure prophylaxis...
Combination Islatravir/Doravirine Maintains Virologic Suppression at 96 Weeks in Patients With HIV-1

Combination Islatravir/Doravirine Maintains Virologic Suppression at 96 Weeks in Patients With HIV-1

A combination of islatravir and doravirine (Pifeltro), taken once daily as a two-drug treatment, showed virologic suppression at 96 weeks in patients with HIV-1 who had not previously received treatment...
Most PrEP Prescriptions Are Being Written by Primary Care Physicians

Most PrEP Prescriptions Are Being Written by Primary Care Physicians

The most common prescriber of preexposure prophylaxis (PrEP) for HIV is primary care physicians, according to recent data from a Medicare database published as a Research Letter in JAMA...
FDA Approves Dolutegravir/Lamivudine for Use in Virologically-Suppressed Adults With HIV-1

FDA Approves Dolutegravir/Lamivudine for Use in Virologically-Suppressed Adults With HIV-1

The FDA has approved dolutegravir/lamivudine (Dovato), a combination HIV drug, for use in place of antiretroviral therapy (ART) in patients with HIV-1 who have already achieved virologic suppression...
FDA Approves Fostemsavir For HIV Treatment

FDA Approves Fostemsavir For HIV Treatment

The FDA has approved a new treatment for HIV-1 patients who are failing their current therapy...

Loading...

© 2021 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use
Do Not Sell My Personal Information